Screener
Spyre Therapeutics, Inc. SYRE Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total other (expense) income | (23,364) | 8,779 |
| Loss before income tax expense | (69,005) | (44,788) |
| Income tax benefit | — | 15 |
| Net loss | $(69,005) | $(44,773) |
| Net loss per share, basic and diluted, Series A Preferred Stock | $(29.66) | $(23.95) |
| Weighted-average Series A non-voting convertible preferred stock outstanding, basic and diluted | 346,045 | 346,045 |
| Net loss per share, basic and diluted, Series B Preferred Stock | $(29.66) | $(23.95) |
| Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted | 16,667 | 16,667 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s business segments — net loss?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — net loss of -$69.01M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — net loss decreased by 54.1% year-over-year, from -$44.77M to -$69.01M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — net loss has grown at a 22.8% compound annual growth rate (CAGR), from -$83.82M to -$155.2M.
- What does business segments — net loss mean?
- The bottom-line financial result for the segment, calculated as total segment revenue minus all associated operating expenses. For early-stage biotech, this represents the cash burn required to advance the therapeutic pipeline.
Ask your AI about Spyre Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude